Can patients with persistent or chronic ITP eventually stop treatment with TPO-RAs?¶
Answer: Yes. STOPAGO — an open prospective multi-center study of 48 patients who had achieved a CR for more than 1 year — showed the following:
At 12 months:
At 12 months, 25 (52.1%; 95% confidence interval [CI], 37.2-66.7) and 14 of 48 patients (29.2%; 95% CI, 17.2-42.3) achieved sustained response off treatment (SROT >30) and sustained CR off treatment (SCROT >100), respectively
— STOPAGO
- Most relapses occurred within 4 weeks after TPO-RA discontinuation, with no major bleeding.
At 4 years:
results show that almost 50% of patients with persistent or chronic ITP who achieved stable CR with TPO-RAs can maintain a sustained response off treatment >4 years after TPO-RA discontinuation, and late relapses are rare.
there were no bleeding events in patients with relapse (nor short or late relapse), and all but 2 patients (1 early and 1 late relapse) achieved CR after rechallenge with TPO-RAs.
— STOPAGO long-term follow-up